Latest Kaiser Health News Stories
Aduhelm, approved by the Food and Drug Administration last month despite questions about its efficacy, could be prescribed to at least 1 million patients a year, for a price tag of about $56 billion. Experts suggest there might be better ways to spend that money.
Exclusive: The head of the National Institute of Allergy and Infectious Diseases says health workers ‘have lived up to the oath they take’ but says shortages of protective gear have contributed to excess deaths.
Hay medicamentos aprobados hace años que podrían investigarse en profundidad para tratar covid. Pero no hay interés porque no generarían grandes ganancias.
Philanthropies are funding studies of cheap, existing medications like the antidepressant fluvoxamine as covid treatments. But early hype about hydroxychloroquine and other repurposed drugs leaves researchers leery of hasty conclusions.
In his campaign, President Joe Biden promised to undo policies, particularly health policies, implemented by former President Donald Trump. Yet, despite immense executive power, reversing four years of action takes time and resources.
Muchos de los principales especialistas en enfermedades infecciosas subestimaron el veloz brote en sus primeras semanas y meses, asumiendo que Estados Unidos, otra vez, saldría ileso.
Scientists learned the wrong lesson from past outbreaks, but Dr. Anthony Fauci doesn’t cast blame.
It’s no worse than the flu, and other deadly disinformation about the coronavirus
El doctor Anthony Fauci, la autoridad máxima en enfermedades infecciosas del país, dice que, si la mayoría de las personas se vacuna, se lograría cierta “normalidad” a mediados de 2021.
In a new interview, the nation’s top infectious disease expert tells us how to survive the coming months and describes how hard it is when people still insist the coronavirus outbreak is “fake news.”
Anthony Fauci is one of the nation’s most trusted voices during public health emergencies. As the head of the National Institutes of Health’s National Institute of Allergy and Infectious Diseases since 1984, Fauci has helped guide the nation through the HIV/AIDS epidemic and more recent outbreaks of Ebola and Zika. In this special episode of KHN’s “What the Health?” podcast, Fauci sits down with KHN Editor-in-Chief Elisabeth Rosenthal to talk about how to navigate the next phase of the coronavirus pandemic and what the incoming Biden administration should do first.
Drugmakers will walk away with massive profits, but much of the pioneering work on mRNA vaccines was done with government money.
Muchos pacientes desconocen estas opciones o simplemente no pueden, o no saben, cómo acceder a ellas. Otros desconfían de los tratamientos no probados.
If you or a loved one has COVID-19, here’s what to consider before seeking experimental treatments.
Data and safety monitoring boards work under a cloak of secrecy meant to prevent undue influence by stakeholders, such as companies or the government. In the Trump era, some worry the anonymity could actually invite it.
Republicans have all but abandoned the Affordable Care Act as a campaign cudgel, judging from their national convention, at least. Meanwhile, career scientists at the federal government’s preeminent health agencies — the Food and Drug Administration, the Centers for Disease Control and Prevention and the National Institutes of Health — are all coming under increasing political pressure as the pandemic drags on. Joanne Kenen of Politico, Mary Ellen McIntire of CQ Roll Call and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss this and more. Plus, Rovner interviews KHN’s Elizabeth Lawrence about the latest KHN-NPR “Bill of the Month” installment.
The FDA, under pressure from the Trump administration, has authorized broader use of convalescent plasma for emergency treatment in COVID patients. But several major hospitals are resisting, saying they’ll opt instead to use the scarce resource to complete a clinical trial.
The nation’s top infectious disease official is confident that an independent panel will base vaccine approval on science, not politics.
El experto en enfermedades infecciosas de más alto rango en el país dice que esto podría ocurrir si los ensayos clínicos en curso producen resultados abrumadoramente positivos.
Los datos para abordar las brechas raciales en la atención en las comunidades más necesitadas, y sus resultados, han sido escasos durante la pandemia.